Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYH2069 Injection in Healthy Participants
NCT07736391Phase 1Active, not recruiting
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- Jan 2026
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and type 2 diabetes mellitus (T2DM) comparing SYH2069 Injection Experimental with Placebo Comparator (2 arms). Primary endpoint: Treatment-related adverse events at Day 50. Started Jan 2026; status: active, not recruiting.
02
Drugs
SYH2069
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07736391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07736391.